Optimal Timing and Sequence of Immunotherapy When Combined with Stereotactic Radiosurgery in the Treatment of Brain Metastases Review uri icon


MeSH Major

  • Brain Neoplasms
  • Radiosurgery


  • Checkpoint immunotherapy (CIT) is an emerging and exciting treatment modality in the treatment of cancer. Much excitement exists in the potential of CIT to revolutionize the treatment and prognosis of brain metastases. The combination of stereotactic radiosurgery (SRS) and CIT has been further studied and showed promise over treatment with either modalities alone. However, several questions arise, particularly the timing at which SRS and CIT are administered relative to each other. This article reviews the current literature and attempts to offer a potential answer to this question.

publication date

  • July 2019



  • Review



  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.wneu.2019.04.093

PubMed ID

  • 31004856

Additional Document Info

start page

  • 397

end page

  • 404


  • 127